Ron Bentsur

2018 - UroGen Pharma Ltd.

In 2018, Ron Bentsur earned a total compensation of $6M as Former Chief Executive Officer at UroGen Pharma Ltd., a 202% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$334,000
Option Awards$1,739,588
Salary$610,200
Other$3,266,324
Total$5,950,112

Bentsur received $3.3M in other compensation, accounting for 55% of the total pay in 2018.

Bentsur also received $334K in non-equity incentive plan, $1.7M in option awards and $610.2K in salary.

Rankings

In 2018, Ron Bentsur's compensation ranked 1,587th out of 14,244 executives tracked by ExecPay. In other words, Bentsur earned more than 88.9% of executives.

ClassificationRankingPercentile
All
1,587
out of 14,244
89th
Division
Manufacturing
558
out of 5,765
90th
Major group
Chemicals And Allied Products
176
out of 2,128
92nd
Industry group
Drugs
139
out of 1,817
92nd
Industry
Pharmaceutical Preparations
102
out of 1,391
93rd
Source: SEC filing on April 26, 2019.

Bentsur's colleagues

We found six more compensation records of executives who worked with Ron Bentsur at UroGen Pharma Ltd. in 2018.

2018

Stephen Mullennix

UroGen Pharma Ltd.

Chief Financial Officer

2018

Gil Hakim

UroGen Pharma Ltd.

Former President

2018

Gary Titus

UroGen Pharma Ltd.

Chief Financial Officer

2018

Peter Pfreundschuh

UroGen Pharma Ltd.

Chief Financial Officer

2018

Peter Pfreundschuh

UroGen Pharma Ltd.

Chief Financial Officer

2018

Mark Schoenberg

UroGen Pharma Ltd.

Chief Medical Officer

News

You may also like